Clinical

Dataset Information

0

Response prediction of third-line cetuximab-based therapy for patients with metastatic colorectal cancer using Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT)


ABSTRACT: Interventions: FDG PET/CT imaging on a dedicated PET/CT system (Siemens Biograph) is to be performed at baseline, and after one cycle and four cycles of Cetuximab therapy. CT is to be performed every 3 months to determine the progression-free survival. Patients will be followed up for at least one year. The FDG PET/CT imaging is non-invasive but requires the patients to fast for 6 hours before the examination and takes up to 3-hour stay. Primary outcome(s): Predictive value of response evaluation (including changes of SUV and MTV values) by FDG PET/CT for progression-free survival (assessed by RECIST criteria 1.1)[All participants be assessed for progression-free survival every 3 months by CT scans (RECIST criteria 1.1) up to one year after enrollment] Study Design: Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Prospective

DISEASE(S): Metastatic Colorectal Cancer Receiving Third-line Therapy With Cetuximab,Cancer-bowel-back Passage (rectum) Or Large Bowel (colon)

PROVIDER: 2457775 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2019-01-23 | GSE101491 | GEO
2011-11-01 | GSE21217 | GEO
2011-11-01 | E-GEOD-21217 | biostudies-arrayexpress
2020-03-18 | GSE135565 | GEO
2020-03-18 | GSE131769 | GEO
2023-12-19 | GSE247303 | GEO
2012-12-01 | E-MEXP-3730 | biostudies-arrayexpress
2018-05-09 | GSE110685 | GEO
2015-04-14 | E-GEOD-54323 | biostudies-arrayexpress
2015-02-09 | E-MTAB-3175 | biostudies-arrayexpress